Niacin has been in clinical use for over 50 years and was the first drug shown in a randomized trial to improve outcomes after MI, but substantial uncertainty remains about its efficacy and safety in the context of current standard medical therapy.
This thesis explores the biochemical efficacy, tolerability and safety of extended release (ER) niacin/laropiprant in the large, randomized HPS2-THRIVE trial. Laropiprant is a prostaglandin D₂ receptor (DP1) antagonist which reduces the ma...Expand abstract
- Publication date:
- Type of award:
- Level of award:
- Awarding institution:
- Oxford University, UK
- Local pid:
- Copyright holder:
- Richard Haynes
- Copyright date:
- This thesis is not currently available via ORA.
The safety, tolerability and biochemical efficacy of extended release niacin and laropiprant in a major randomised clinical trial
If you are the owner of this record, you can report an update to it here: Report update to this record